NCT00347932View on ClinicalTrials.gov

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

PHASE3CompletedINTERVENTIONAL
Enrollment

957

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Acute Bacterial Conjunctivitis
Interventions
DRUG

ISV-403

Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.

DRUG

Vehicle

Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00347932 - A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. | Biotech Hunter | Biotech Hunter